At ASCO 2020 meeting, the new final survival results of the SPARTAN study were reported. When we look at overall survival in SPARTAN, the use of apalutamideprolongs survival from 60 months to 74 months – that is a 14-month survival advantage, with a hazard ratioof 0.78. Earlier reports have shown significant advantages in reduction of ...

CheckMate 9LA is the second trial in a row of trials investigating the role of immunotherapy combinations in patients with non-small cell lung cancer (NSCLC). At the preplanned interim analysis after 8.1 months, overall survival was significantly prolonged with the combination of ipilimumab (IPI) and nivolumab (NIVO) and chemo vs chemo alone as front-line therapy in unselected patients with advanced ...

Multiple myeloma and therapeutic decisions during COVID-19

COVID-19 | Best Practice Nordic | 5. Jun 2020 kl. 10:52 | ,

Patients with multiple myeloma (MM) could be in an increased risk of a more severe COVID-19 infection and of more severe associated complications. In this COVID-19 perspective, associate professor Annette Juul Vangsted goes through newly made clinical guidelines during the COVID-19 pandemic created by The European Myeloma Network.  Multiple myeloma is an incurable cancer in ...

MEDtalk: Background and study design of the SPARTAN study

ASCO20 Virtual | Best Practice Nordic | 3. Jun 2020 kl. 12:35 | ,

Eric J. Small, MD and principal investigator of the SPARTAN study explains the background and study design of the SPARTAN study, where the efficiency and safety of apalutamide for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) was ...

The COVID-19 pandemic has changed the format of this year’s ASCO Annual Meeting. The conference ran from 29 – 31 May under the theme ‘Unite and Conquer: Accelerating Progress Together.’ This year’s scientific program featured more than 250 oral presentations and 2,500 poster presentations in 24 disease-based and specialty tracks. In the opening session on ...

Results from a post hoc analysis of the SPARTAN Phase III study of apalutamide showed that regardless of genetic subclass, the treatment significantly improved the metastasis-free survival of patients with non-metastatic castration-resistant prostate cancer (nmCRPC). For more than 50% of patients treated with apalutamide, a ≥ 90% reduction in PSA was observed. The results was ...

Three new therapeutic agents for the treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC), apalutamid, darolutamid and enzalutamid, have recently been FDA approved. Not alone are the therapies new, they also open up to the treatment of a whole new group of patients, for whom there was no treatment possibility earlier. It raises several questions. On ...

Dr. David Fajgenbaum was close to dying of Castleman’s disease, but ended up pursuing a cure for this rare disease. In this ASCO podcast episode, Dr. David Fajgenbaum, American immunologist and author, tells about his involvement in finding a cure for the rare Castleman’s disease. He discusses his methodical experiences and relates them to the ...

Martin Reck, MD and Ph.D at the German Center of Lung Research, presented at this year’s ASCO20 Virtual Scientific program the first results from the CheckMate 9LA trial – a randomized trial investigating the combination of a limited cause of chemotherapy together with nivolumab and ipilimumab as first line treatment for patients with advanced non ...

As previously described in the Danish journal BestPractice Onkologi in August 2017, Merkel cell carcinomas (MCC) are a very aggressive skin-associated cancer type. They are characterized by being rapidly proliferative with an extremely high risk of spread and rapidly declining survival odds parallel to regional and remote spread. For patients with resectable local or regional ...

#Senaste tidskrift

BestPractice Nordic

Nr. 1 • mars 2020
1. Årgang
  • Hjärt-kärlsjukdom
  • Blodtrycksmätning
  • Inkretinbehandling